Company intelligence / Profile preview
Eppin Pharma
Durham, North Carolina, United Stateseppinpharmainc.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Eppin Pharma's lead candidate EP055 is a small organic compound that binds to EPPIN protein on sperm, resulting in loss of sperm motility. The company has completed a successful proof-of-concept study in primates at the Oregon National Primate Research Center in April 2018 and is preparing for human clinical trials[2][6].
- Therapeutic areas
- Men's Health
- Modalities
- Small organic compounds
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Male Contraceptive Initiative (MCI)
Beyond the preview
Go deeper on Eppin Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eppin Pharma.